Hospira, Inc the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today reported results for the second quarter ended June 30, 2015. For the second quarter of 2015, net sales were $1.2 billion, and adjusted* diluted earnings per share were $0.85. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.) On a U.S. Generally Accepted Accounting Principles (GAAP) basis, second-quarter 2015 diluted earnings per share were $0.82.
Hospira and Pfizer Inc. announced in the first quarter of 2015 that the two companies had entered into a merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion. During the second quarter, Hospira's shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer Inc. at a special meeting of stockholders held on May 13, 2015. The merger remains subject to customary closing conditions, including regulatory approvals in several jurisdictions, and is expected to close in the second half of 2015.
